ConductScience.org, home

Paper22825331

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Prevo R and 7 others. Cancer Biol Ther, 2012. Cited by 200 papers, by iCite.

Cite this record

ConductScience Library. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Papers, record 22825331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22825331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
PubMed
Journal
Cancer Biol Ther
PubMed
Year
2012
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
200
iCite
Relative citation ratio, by iCite
4.56
iCite
Revised in PubMed
2025-12-18
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Prevo RRemko
2Fokas EEmmanouil
3Reaper PMPhilip M
4Charlton PAPeter A
5Pollard JRJohn R
6McKenna WGW Gillies
7Muschel RJRuth J
8Brunner TBThomas B

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
DeoxycytidineMajor topic
Pancreatic NeoplasmsMajor topic
PyrazinesMajor topic
SulfonesMajor topic
Ataxia Telangiectasia Mutated Proteins
Cell Cycle Checkpoints
Cell Cycle Proteins
Cell Hypoxia
Cell Line, Tumor
Combined Modality Therapy
DNA Damage
DNA Repair
Humans
Phosphorylation
Protein Serine-Threonine Kinases
Radiation-Sensitizing Agents
Signal Transduction
Gemcitabine

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
11563Cancer Research UKUnited KingdomPubMed
G0700730Medical Research CouncilUnited KingdomPubMed

Source PubMed

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in41412153Correction.https://conductscience.org/library/papers/41412153

Source PubMed

Download CSV of comments and corrections

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
111072146Pancreatic tumors show high levels of hypoxia.Int J Radiat Oncol Biol Phys2000https://conductscience.org/library/papers/11072146PubMed
220606093Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.J Clin Oncol2010https://conductscience.org/library/papers/20606093PubMed
319718024Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53.Nat Genet2009https://conductscience.org/library/papers/19718024PubMed
421820372Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs.Mol Oncol2011https://conductscience.org/library/papers/21820372PubMed
515084616Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.J Clin Oncol2004https://conductscience.org/library/papers/15084616PubMed
618256616DNA repair pathways as targets for cancer therapy.Nat Rev Cancer2008https://conductscience.org/library/papers/18256616PubMed
711481349Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.J Clin Oncol2001https://conductscience.org/library/papers/11481349PubMed
820501833Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.Cancer Res2010https://conductscience.org/library/papers/20501833PubMed
916648548Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.Mol Cancer Ther2006https://conductscience.org/library/papers/16648548PubMed
1015073105Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.Clin Cancer Res2004https://conductscience.org/library/papers/15073105PubMed
1120615227The role of radiotherapy in multimodal treatment of pancreatic carcinoma.Radiat Oncol2010https://conductscience.org/library/papers/20615227PubMed
1221430696Strategies to improve radiotherapy with targeted drugs.Nat Rev Cancer2011https://conductscience.org/library/papers/21430696PubMed
1319305158Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints.Cell Cycle2009https://conductscience.org/library/papers/19305158PubMed
1418632646Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.Cancer Res2008https://conductscience.org/library/papers/18632646PubMed
1521306953Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.Lancet Oncol2011https://conductscience.org/library/papers/21306953PubMed
1621255190Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs.Cancer Sci2011https://conductscience.org/library/papers/21255190PubMed
1722120667Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.Nat Struct Mol Biol2011https://conductscience.org/library/papers/22120667PubMed
1819806144Epidemiology of pancreatic cancer: an overview.Nat Rev Gastroenterol Hepatol2009https://conductscience.org/library/papers/19806144PubMed
1917452677Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol2007https://conductscience.org/library/papers/17452677PubMed
2021730979Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.Br J Cancer2011https://conductscience.org/library/papers/21730979PubMed

See all 37 referencesDownload CSV of references

Cited by132

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 200 citations.

PMIDTitleJournalYearIn PapersSource
42980881
Quantitative systems pharmacology modeling identifies synthetic lethality opportunities with DNA damage response inhibitors in ATM-deficient chronic lymphocytic leukemia - a computational simulation study.
J Pharmacokinet Pharmacodyn2026https://conductscience.org/library/papers/42980881PubMed
42376674DNA damage response inhibitors in pancreatic cancer: progress and challenges.Front Oncol2026https://conductscience.org/library/papers/42376674PubMed
42244588Transient ATR inhibition following ionizing radiation enhances immune-mediated antitumor response and survival.bioRxiv2026https://conductscience.org/library/papers/42244588PubMed
42082831Succinate dehydrogenase loss suppresses pyrimidine biosynthesis via succinate-mediated inhibition of aspartate transcarbamylase.Nat Metab2026https://conductscience.org/library/papers/42082831PubMed
41787655Inhibition of Autophagy Reveals ATR Protein Kinase as a Key Mediator of Cisplatin Sensitivity in Osteosarcoma.Cancer Med2026https://conductscience.org/library/papers/41787655PubMed
41614897Replication Stress in Cancer: Mechanistic Insights and Therapeutic Opportunities for Radiosensitization.Curr Issues Mol Biol2026https://conductscience.org/library/papers/41614897PubMed
41575477Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules.Mol Divers2026https://conductscience.org/library/papers/41575477PubMed
41563386Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.Clin Cancer Res2026https://conductscience.org/library/papers/41563386PubMed
41120356And-1 coordinates with polymerase δ to regulate nucleotide excision repair and UVB-induced skin tumorigenesis.Nat Commun2025https://conductscience.org/library/papers/41120356PubMed
40256842Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics.J Enzyme Inhib Med Chem2025https://conductscience.org/library/papers/40256842PubMed
39613844ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment.Br J Cancer2025https://conductscience.org/library/papers/39613844PubMed
39410888Non-fused Pyrimidine Derivatives as Potential Pharmacological Entities: A Review.Curr Top Med Chem2025https://conductscience.org/library/papers/39410888PubMed
39223250Cancer drug-tolerant persister cells: from biological questions to clinical opportunities.Nat Rev Cancer2024https://conductscience.org/library/papers/39223250PubMed
38843833The ribotoxic stress response drives UV-mediated cell death.Cell2024https://conductscience.org/library/papers/38843833PubMed
38321933DNA hypomethylation activates Cdk4/6 and Atr to induce DNA replication and cell cycle arrest to constrain liver outgrowth in zebrafish.Nucleic Acids Res2024https://conductscience.org/library/papers/38321933PubMed
37993260Decline of DNA damage response along with myogenic differentiation.Life Sci Alliance2024https://conductscience.org/library/papers/37993260PubMed
37511442Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis.Int J Mol Sci2023https://conductscience.org/library/papers/37511442PubMed
37461317Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells.Elife2023https://conductscience.org/library/papers/37461317PubMed
36768638The ATR Inhibitor VE-821 Enhances the Radiosensitivity and Suppresses DNA Repair Mechanisms of Human Chondrosarcoma Cells.Int J Mol Sci2023https://conductscience.org/library/papers/36768638PubMed
36606678Targeting the DNA damage response for cancer therapy.Biochem Soc Trans2023https://conductscience.org/library/papers/36606678PubMed

See all 132 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ATR545PubTator's text mininghttps://conductscience.org/library/genes/545NCBI Gene
CHEK11111PubTator's text mininghttps://conductscience.org/library/genes/1111NCBI Gene
RAD515888PubTator's text mininghttps://conductscience.org/library/genes/5888NCBI Gene
TP53BP17158PubTator's text mininghttps://conductscience.org/library/genes/7158NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22825331

GET https://conductscience.org/api/papers/v1/22825331/references?page=2